Inhibitor Therapeutics, Inc. filed its 10-K on Mar 30, 2022 for the period ending Dec 31, 2021. In this report its auditor, Cherry, Bekaert & Holland, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.085 USD | +6.25% |
|
0.00% | -7.61% |
1st Jan change | Capi. | |
---|---|---|
-7.61% | 14.65M | |
+20.63% | 126B | |
+24.16% | 27.95B | |
-20.17% | 20.5B | |
-16.06% | 17.12B | |
-18.07% | 16.1B | |
-47.70% | 14.97B | |
+11.92% | 14.84B | |
+58.32% | 14.38B | |
+149.98% | 12.37B |
- Stock Market
- Equities
- INTI Stock
- News Inhibitor Therapeutics, Inc.
- Inhibitor Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt